

1

Agenda - Day 1 **AUGUST 15 - DECISION ANALYSIS** Session 1: Introduction Agenda, brief background, and goals for masterclass; review of Decision 8:00 - 8:30 a.m. ET Analysis & Portfolio Management survey Session 2: Decision-making Under Uncertainty And Risk 8:30 - 10:00 a.m. ET The value of decision framing and the Decision Quality (DQ) cycle TEA/COFFEE BREAK 10:00 - 10:15 a.m. ET Session 3: Introduction to Decision Analysis and Decision Trees A discipline oriented toward strategy selection on the basis of eNPV maximization under conditions of uncertainty and risk; calculating eNPV 10:15 a.m. - 12:00 p.m. ET using Decision Trees Software: Precision Tree Convight 2022 © Project & Portfolio Value Creation. EMD Serono & Merck KGaA; August 15-18, 2022

	Agenda – Day 2	
	AUGUST 16 – DECISION ANALYSIS	
	sis & Risk Management sk decomposition, SME risk elicitation, biases; nd portfolio risk	8:00 – 9:45 a.m. ET
TEA/COFFEE BREAK		9:45 – 10:00 a.m. ET
		10:00 – 11:00 a.m. ET
	stic Integrated Asset Valuation (II) to conduct sensitivity analysis of uncertainties and risks ons	11:00 a.m. – 12:00 p.m. ET
Software: Precision	ree	
Copyright 2022 © Project & Po All rights reserved.	entrolio Value Creation. EMD Serono & Merck KGaA; August	15-18, 2022 3

	Agenda – Day 3		
_	AUGUST 17 – PORTFOLIO MANAGEMENT		
	Session 7: Crossing The Chasm – From Drug Discovery Through Clinical Development Cultivating and embedding a Portfolio Management mindset across the entire value chain	8:00 – 9:00 a.m. ET	
	Session 8: CREOPM TM A holistic Portfolio Management framework oriented toward portfolio value maximization and capability maturation	9:00 – 10:15 a.m. ET	
\mathbb{N}	TEA/COFFEE BREAK	10:15 – 10:30 a.m. ET	
	Session 9: Project Prioritization Searching for the best rank order of projects to create portfolio value within defined resource constraints using Multiple Objective Decision Analysis (MODA)	10:30 a.m. – 12:00 p.m. ET	
	Copylight 2022 © Project & Portfolio Value Creation. EMD Serono & Merck KGaA; Augus	st 15-18, 2022 4	- PP\/(

Agenda - Day 4

AUGUST 18 – PORTFOLIO MANAGEMENT				
Session 10: Deterministic Portfolio Optimization Searching for the best combination of projects to maximize portfolio value within defined resource constraints using Linear Programming (LP) Software: Evolver	8:00 – 10:00 a.m. ET			
TEA/COFFEE BREAK	10:00 – 10:15 a.m. ET			
Session 11: Strategic, Portfolio, And Business Plans The importance of actionable and interdependent strategic, portfolio, and business plans	10:15 – 11:00 a.m. ET			
Session 12: Decision-making and Portfolio Management Capability Maturity Models Diagnosis of organizational decision-making and Portfolio Management capability maturity models	11:00 a.m. – 11:45 a.m. ET			
Session 13: Final Q&A Any other business	11:45 a.m. – 12:00 p.m. ET			



Copyright 2022 © Project & Portfolio Value Creation.
All rights reserved.

EMD Serono & Merck KGaA; August 15-18, 2022

5

Dr. Richard Bayney – President, PPVC



Dr. Richard Bayney is President & Founder of Project & Portfolio Value Creation (PPVC), a consulting boutique providing training and education in Project, Program, Portfolio, Resource, and Risk Management as well as Business, Strategic, Portfolio, and Scenario Planning services. He is an adjunct faculty member at the University of Pennsylvania lecturing to graduate and executive students in 'Project Portfolio Management'. He delivers masterclasses in Decision Analysis & Portfolio Management to a broad range of industry communities in US, EU, and Asia. Richard is a frequent speaker in 'Portfolio & Resource Management, Risk Analysis & Risk Management, and Strategic Planning in Drug Development' and consults across several industries including Pharma & Biotech, Consumer Care, Medical Devices & Diagnostics, and Agriculture.

Dr. Bayney is a 23-year veteran of the Pharmaceutical & Biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson Pharmaceutical Research & Development. In his previous position at Johnson & Johnson, Richard was Vice President, Portfolio Management & Decision Analysis. He has spent 25 years building and leading departments in Strategic Planning, Decision Analysis, and Portfolio Management, 2 years as an International Project Manager for a marketed cardiovascular drug, and 10 years in Molecular Biology research into gene expression in drug detoxification systems and in Alzheimer's Disease.

His first co-authored book, titled 'Enterprise Project Portfolio Management: Building Competencies For R&D And IT Investment Success' was published by J. Ross in 2012.


Dr. Bayney obtained his M.Sc. and Ph.D. from the University of London, MBA from Columbia University, and PMP from the Project Management Institute.

Copylight 2022 © Project & Portfolio Value Creation.
All rights reserved.


EMD Serono & Merck KGaA; August 15-18, 2022


6






PPVC's Mission, Vision, and Values MISSION We exist to enhance an organization's protracted performance in maximizing the value of its assets through the application of superior strategic and analytic skills VISION Within the next decade, we want to be known as a premier provider of services that are distinguished by the uniqueness of their prescription and application VALUES We believe that every organization is unique and hold dear to the philosophy that we must understand people and culture before prescribing solutions and tools ght 2022 © Project & Portfolio Value Creation. EMD Serono & Merck KGaA; August 15-18, 2022







PORTFOLIO MANAGEMENT SPIDER - PRIMARY DIMENSIONS
DISCUSSIONANCE

PORTFOLIO MANAGEMENT SPIDER - P